Popular Articles

Stem Cell Therapeutics Receives Clearance From Health Canada To Proceed With The Phase IIb Clinical Stroke Trial
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)("SCT" or "the Company") has received a No Objection Letter ("NOL") from Health Canada for the modified REGENESIS protocol using NTx®-265 for a Phase IIb clinical trial treating acute ischemic stroke.
new payday loan lenders
Cardica Announces Publication Of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
Cardica, Inc. (Nasdaq: CRDC) announced that the full results of the PAS-Port system multi-center pivotal trial, known as the EPIC trial, were published in the July issue of the peer-reviewed publication The Journal of Thoracic and Cardiovascular Surgery. The PAS-Port system, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2008, creates a secure connection, or anastomosis, between a vein graft and the aorta, the main artery in the human body, during coronary artery bypass grafting (CABG) procedures.
News of the day
First U.K. Stem Cell Awareness Rally To Take Place In Manchester, England On August 9th, 2009
In what will be the Stem Cell Awareness Association"s seventh awareness rally, past patients, interested physicians, and prospective patients will meet in Manchester to learn about stem cell technologies and discuss the various current treatments available throughout the world.
Nutrition

Nucletron Releases Comprehensive Film-and Volume-Based Planning System For Wide Variety Of Brachy Solutions

Nucletron, a knowledge-based leader in radiation oncology, announced a new release of Oncentra(R) Brachy, a comprehensive film- and volume-based treatment planning system to optimize cancer treatment planning for brachytherapy. Oncentra Brachy, the world"s first fully DICOM-compatible treatment planning system, is a user-friendly Windows-based planning system that features state-of-the-art optimization algorithms to ensure efficient treatment. Oncentra Brachy is adaptable to any clinical workflow. As well as advanced 3D contouring and margining tools, Oncentra Brachy fully supports film-based (2D) treatment planning. The system allows for planning of a wide variety of brachytherapy treatments. Oncentra Brachy is fully geared up towards Intensity Modulated Brachytherapy (IMBT). "We have set a new benchmark in brachytherapy treatment planning," said Jos Lamers, chief executive officer of Nucletron. "We have worked with our clinical partners to develop a solution that migrates PLATO users to a new platform that fits the demands of all clinics. As part of our full range of brachytherapy solutions, Oncentra Brachy is a key element of our efforts in improving patient care." Nucletron will display and demonstrate Oncentra Brachy throughout the 2009 GEC ESTRO in Porto, Portugal, from 13 to 16 May 2009, and at ABS 2009 in Toronto, Canada, from 31 May to 2 June 2009. Nucletron


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):